Regeneron Has Solid Growth Prospects, Says Roth Capital Analyst

In a research note released this morning, Roth Capital reiterated coverage on Regeneron Pharmaceuticals (REGN) with a Buy rating and a price target of $382.00, following the announcement that Regeneron has submitted for EU marketing authorization for EYLEA for the treatment of macular edema following BRVO.

Roth’s analyst Dr. Joseph Pantginis believes that Regeneron has solid growth prospects based on: 1) approved and late stage products, 2) a deep pipeline, 3) expansion of indications for current products, 4) strong partners and, 5) strong cash management.

According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, Dr. Joseph Pantginis, who covers REGN, has a one-year average return of 1.5% and a 44% success rate.

REGN Chart


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts